Candel Therapeutics
Market cap $424M 78.4M shares (10-Q, Nov 5, 2026) × $5.40 close Nov 17, 2026
Most recent annual filing: 2026-03-12
- linoserpaturev interim4Q 2026linoserpaturev interim, 4Q 2026, notable
- aglatimagene besadenovec corporate updateNov 2026aglatimagene besadenovec corporate update, Nov 2026, routine
- CADL corporate filingDec 2026CADL corporate filing, Dec 2026, notable
- aglatimagene besadenovec financingMar 31, 2027aglatimagene besadenovec financing, Mar 31, 2027, routine
- aglatimagene besadenovec BLA filingin the middle of 2027aglatimagene besadenovec BLA filing, in the middle of 2027, major
- PrTK03 presumably CAN-2409 filingmid-2027PrTK03 presumably CAN-2409 filing, mid-2027, material
- CADL corporate updateSep 2027CADL corporate update, Sep 2027, routine
- CADL corporate updateOct 1, 2027CADL corporate update, Oct 1, 2027, routine
- aglatimagene besadenovec financingDec 31, 2027aglatimagene besadenovec financing, Dec 31, 2027, routine
- CADL corporate update1Q 2028CADL corporate update, 1Q 2028, routine
- Cash runway corporate update2Q 2028Cash runway corporate update, 2Q 2028, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (4 active programs)
linoserpaturev
CAN-3110 · rQNestin34.5v.2Alpha-201 Macro1
- Undisclosed indication
Technology platforms
enLIGHTEN Discovery Platform
Systematic, iterative HSV-based viral immunotherapy discovery platform leveraging human biology, computational biology, and advanced analytics to create new viral immunotherapy candidates for solid tumors. Generates both replication-defective and replication-competent agents. Multiple preclinical candidates include Alpha-201 Macro1 (CD47/SIRPα), a TLS-inducing multimodal immunotherapy, and an IL-12/IL-15 encoding candidate.
Targets: IL-12, IL-15, CD47, SIRPα
enLIGHTEN Discovery Platform · University of Pennsylvania
Systematic, iterative herpes simplex virus-based platform leveraging human biology and advanced analytics; focus area: novel viral immunotherapies for cancer
enLIGHTEN
Systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create multimodal biological immunotherapies for solid tumors; deconvolutes tumor microenvironment characteristics and translates them into optimized multi-gene payloads for specific indications.
Adenovirus viral immunotherapy platform
Off-the-shelf engineered adenovirus platform for intratumoral administration designed to induce immunogenic cell death and systemic anti-tumor immune response; focus area: solid tumors / oncology
HSV viral immunotherapy platform · MGB
Off-the-shelf engineered herpes simplex virus (HSV) platform for intratumoral administration; includes rQNestin (oncolytic HSV) licensed from MGB; focus area: solid tumors / oncology
rQNestin · MGB
Genetically modified oncolytic herpes simplex virus platform licensed from MGB; being developed for treatment of certain types of cancers
enLIGHTEN Discovery
Discovery platform generating novel oncolytic and immunotherapy candidates targeting solid tumors; specific candidates not yet named.
Discontinued (1)
- aglatimagene besadenovec — Pancreatic Ductal Adenocarcinoma · paused further clinical development in October 2025 in context of portfolio prioritization unless externally funded
Capital (as filed)
- Cash
- $203M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$23.1M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $203M cash per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (3)
- 2026-11-17 UPDATE: Candel Therapeutics (CADL) - The Anchor Halves Its Stake 🔒 Paid
- 2026-11-13 UPDATE: Candel Therapeutics (CADL) - The Clock Slips, the ATM Reloads 🔒 Paid
- 2026-10-12 Candel Therapeutics (CADL) - Scientific Deep Dive for Aglatimagene Besadenovec (CAN-2409) and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (3 calls)
Every verdict Biotech Distilled has published on Candel Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-10-12 Watch Candel Therapeutics (CADL) - Scientific Deep Dive for Aglatimagene Besadenovec (CAN-2409) and Pipeline Products PrTK03 met its SPA primary endpoint but most of the DFS benefit appears at the protocol biopsy window, clinical endpoints (metastasis, salvage, OS) remain undecided, and the balance sheet reaches the FDA decision with nothing to spare.
- 2026-11-13 Avoid UPDATE: Candel Therapeutics (CADL) - The Clock Slips, the ATM Reloads The BLA slipped past Q4 2026 for a CMC/assay reason (a named PASS trigger), the RTW and Trinity financing now looks mistimed against the review clock, and a fresh $50M ATM opens dilution before any de-risking event.
- 2026-11-17 Avoid UPDATE: Candel Therapeutics (CADL) - The Anchor Halves Its Stake RTW halved its equity stake before the BLA slip was disclosed, the stock now sits below the Trinity covenant line, and the open ATM means dilution comes at lower prices before any de-risking event.
- Avoid call · opened Nov 13, 2026 at $6.20 · -12.9% vs XBI -3.5% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (1 quote from 1 filing)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“We expect to present data on potential long-term survivors in the fourth quarter of 2026.”
matched to linoserpaturev (CAN-3110) · interim data
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (23)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Oct 22, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 12, 2026ReleaseCandel Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights→ BD updateSummary on the 8-K
- Nov 12, 20268-KCurrent report: other events→ BD updateCandel pushed its aglatimagene BLA from Q4 2026 to "mid-2027" — a 6-9 month slip that delays the entire approval timeline and tightens an already razor-thin cash runway, while simultaneously reopening a fresh $50M ATM program after exhausting the prior one.
- Nov 12, 20268-KCurrent report: results of operations · EX-99.1→ BD updateSummary on the 8-K
- Nov 12, 2026424B5Prospectus supplement (offering)→ BD updateSummary on the 8-K
- Nov 12, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 6, 2026ReleaseCandel Therapeutics Presents SITC 2026 Data Highlighting Systemic Immune Activation and Survival Outcomes Across Clinical-Stage Portfolio
- Oct 29, 2026ReleaseCandel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate CancerBD extracted 1 program update from this document → CADL pipeline
- Oct 27, 2026ReleaseCandel Therapeutics to Present at November Investor Conferences
- Oct 22, 2026ReleaseCandel Therapeutics Appoints Maria Ostrovsky as General Counsel
- Sep 10, 20268-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
- Sep 9, 20268-KCurrent report: Reg FD disclosure · EX-99.1
- Aug 13, 20268-KCurrent report: results of operations · EX-99.1
- Aug 13, 202610-QQuarterly report
- Jun 24, 20268-KCurrent report: shareholder vote
- Jun 16, 20268-KCurrent report: officer / director change
- May 15, 20268-KCurrent report: Reg FD disclosure · EX-99.1
- May 14, 20268-KCurrent report: results of operations · EX-99.1
- May 14, 202610-QQuarterly report
- Apr 29, 2026DEFA14AProxy soliciting material
- Apr 29, 2026DEF 14AProxy statement
- Mar 18, 2026SCHEDULE 13D/A13D amendment
- Mar 12, 20268-KCurrent report: results of operations · EX-99.1
- Mar 12, 202610-KAnnual report
6 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment→ BD updateRTW Investments — Candel's royalty financier and former 8.8% anchor holder — quietly cut its equity stake nearly in half to 4.2% as of September 30. When the entity that gets paid $100M only on approval is selling stock, the read-through is not friendly.
- Jul 27, 2026SCHEDULE 13GPassive >5% holder (13G)
- May 15, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 29, 2026ARSAnnual report to shareholders
- Apr 27, 2026SCHEDULE 13G/A13G amendment
- Mar 12, 2026S-8Employee plan registration